Yaghmaei Hessam, Bahanesteh Amirhossein, Soltanipur Masood, Takaloo Sobhan, Rezaei Mahdi, Siadat Seyed Davar
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Int J Hepatol. 2024 Oct 16;2024:4183880. doi: 10.1155/2024/4183880. eCollection 2024.
One of the most common chronic liver diseases is nonalcoholic fatty liver disease (NAFLD), which affects many people around the world. Gut microbiota (GM) dysbiosis seems to be an influential factor in the pathophysiology of NAFLD because changes in GM lead to fundamental changes in host metabolism. Therefore, the study of the effect of dysbiosis on the pathogenicity of NAFLD is important. European clinical guidelines state that the best advice for people with NAFLD is to lose weight and improve their lifestyle, but only 40% of people can achieve this goal. Accordingly, it is necessary to provide new treatment approaches for prevention and treatment. In addition to dietary interventions and lifestyle modifications, GM modification-based therapies are of interest. These therapies include probiotics, synbiotics, fecal microbiota transplantation (FMT), and next-generation probiotics. All of these treatments have had promising results in animal studies, and it can be imagined that acceptable results will be obtained in human studies as well. However, further investigations are required to generalize the outcomes of animal studies to humans.
最常见的慢性肝病之一是非酒精性脂肪性肝病（NAFLD），它影响着世界各地的许多人。肠道微生物群（GM）失调似乎是NAFLD病理生理学中的一个影响因素，因为GM的变化会导致宿主代谢的根本改变。因此，研究失调对NAFLD致病性的影响很重要。欧洲临床指南指出，对NAFLD患者的最佳建议是减肥并改善生活方式，但只有40%的人能够实现这一目标。因此，有必要提供新的预防和治疗方法。除了饮食干预和生活方式改变外，基于GM修饰的疗法也备受关注。这些疗法包括益生菌、合生元、粪便微生物群移植（FMT）和下一代益生菌。所有这些治疗方法在动物研究中都取得了有前景的结果，可以想象在人体研究中也会获得可接受的结果。然而，需要进一步研究才能将动物研究的结果推广到人类。
